RS67385B1 - Antitela koja se vezuju za citrulinisani histon 2a i/ili 4 - Google Patents
Antitela koja se vezuju za citrulinisani histon 2a i/ili 4Info
- Publication number
- RS67385B1 RS67385B1 RS20251114A RSP20251114A RS67385B1 RS 67385 B1 RS67385 B1 RS 67385B1 RS 20251114 A RS20251114 A RS 20251114A RS P20251114 A RSP20251114 A RS P20251114A RS 67385 B1 RS67385 B1 RS 67385B1
- Authority
- RS
- Serbia
- Prior art keywords
- antibody
- seq
- binding fragment
- antibodies
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813597.0A GB201813597D0 (en) | 2018-08-21 | 2018-08-21 | Antibody |
| GBGB1900983.6A GB201900983D0 (en) | 2019-01-24 | 2019-01-24 | Antibody |
| EP19756180.6A EP3841120B1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
| PCT/EP2019/072302 WO2020038963A1 (en) | 2018-08-21 | 2019-08-20 | Antibodies binding to citrullinated histone 2a and/or 4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67385B1 true RS67385B1 (sr) | 2025-11-28 |
Family
ID=67688785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20251114A RS67385B1 (sr) | 2018-08-21 | 2019-08-20 | Antitela koja se vezuju za citrulinisani histon 2a i/ili 4 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20210395350A1 (enExample) |
| EP (2) | EP4659807A3 (enExample) |
| JP (2) | JP7434328B2 (enExample) |
| KR (2) | KR20250148711A (enExample) |
| CN (2) | CN112930356B (enExample) |
| AU (3) | AU2019326740B2 (enExample) |
| CA (1) | CA3110013A1 (enExample) |
| DK (1) | DK3841120T3 (enExample) |
| ES (1) | ES3048210T3 (enExample) |
| FI (1) | FI3841120T3 (enExample) |
| HR (1) | HRP20251346T1 (enExample) |
| IL (2) | IL322482A (enExample) |
| LT (1) | LT3841120T (enExample) |
| MX (3) | MX2025007881A (enExample) |
| PT (1) | PT3841120T (enExample) |
| RS (1) | RS67385B1 (enExample) |
| SG (1) | SG11202101652PA (enExample) |
| SI (1) | SI3841120T1 (enExample) |
| SM (1) | SMT202500388T1 (enExample) |
| WO (1) | WO2020038963A1 (enExample) |
| ZA (1) | ZA202101051B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| CN112930356B (zh) | 2018-08-21 | 2025-03-21 | 奇特里尔私人有限公司 | 与瓜氨酸化的组蛋白2a和/或4结合的抗体 |
| WO2020072993A1 (en) | 2018-10-05 | 2020-04-09 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application |
| WO2021209465A1 (en) * | 2020-04-14 | 2021-10-21 | Universiteit Maastricht | Peptide for the treatment of net-associated diseases |
| JP2023533504A (ja) * | 2020-07-07 | 2023-08-03 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルムの処置および予防のための併用療法 |
| GB202012326D0 (en) | 2020-08-07 | 2020-09-23 | Citryll B V | Diagnostic |
| EP4085973A1 (en) | 2021-05-04 | 2022-11-09 | Citryll B.V. | Inhibition of eosinophil extracellular traps |
| WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
| EP4442705A1 (en) | 2023-04-03 | 2024-10-09 | Citryll B.V. | Dosage |
| GB202318703D0 (en) | 2023-12-07 | 2024-01-24 | Citryll B V | Diagnostic agent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5364870B2 (ja) | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| US8629246B2 (en) | 2007-09-26 | 2014-01-14 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| CN102056944A (zh) | 2008-06-04 | 2011-05-11 | 莫蒂克斯特私人有限公司 | 抗炎症药剂 |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| ES2667258T3 (es) | 2009-09-10 | 2018-05-10 | Ucb Biopharma Sprl | Anticuerpos multivalentes |
| EP2332987A1 (en) | 2009-12-10 | 2011-06-15 | ModiQuest B.V. | Anti-inflammatory agents directed against citrullinated epitopes |
| GB201410520D0 (en) * | 2014-06-12 | 2014-07-30 | Univ London Queen Mary | Antibody |
| JP7037940B2 (ja) | 2014-12-11 | 2022-03-17 | シトリル べー．フェー． | 特発性肺線維症の治療方法 |
| WO2017021552A1 (en) | 2015-08-06 | 2017-02-09 | Novimmune Sa | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| CN112930356B (zh) | 2018-08-21 | 2025-03-21 | 奇特里尔私人有限公司 | 与瓜氨酸化的组蛋白2a和/或4结合的抗体 |
| CN117396221A (zh) * | 2021-05-04 | 2024-01-12 | 奇特里尔私人有限公司 | 嗜酸性粒细胞陷阱的抑制 |
| WO2022233931A1 (en) | 2021-05-04 | 2022-11-10 | Citryll B.V. | Inhibition of eosinophilic traps |
-
2019
- 2019-08-20 CN CN201980070130.3A patent/CN112930356B/zh active Active
- 2019-08-20 EP EP25196231.2A patent/EP4659807A3/en active Pending
- 2019-08-20 RS RS20251114A patent/RS67385B1/sr unknown
- 2019-08-20 MX MX2025007881A patent/MX2025007881A/es unknown
- 2019-08-20 MX MX2021001902A patent/MX2021001902A/es unknown
- 2019-08-20 HR HRP20251346TT patent/HRP20251346T1/hr unknown
- 2019-08-20 WO PCT/EP2019/072302 patent/WO2020038963A1/en not_active Ceased
- 2019-08-20 SM SM20250388T patent/SMT202500388T1/it unknown
- 2019-08-20 FI FIEP19756180.6T patent/FI3841120T3/fi active
- 2019-08-20 CN CN202510240710.XA patent/CN120058926A/zh active Pending
- 2019-08-20 ES ES19756180T patent/ES3048210T3/es active Active
- 2019-08-20 PT PT197561806T patent/PT3841120T/pt unknown
- 2019-08-20 AU AU2019326740A patent/AU2019326740B2/en active Active
- 2019-08-20 KR KR1020257029356A patent/KR20250148711A/ko active Pending
- 2019-08-20 KR KR1020217008362A patent/KR102871821B1/ko active Active
- 2019-08-20 US US17/269,509 patent/US20210395350A1/en not_active Abandoned
- 2019-08-20 IL IL322482A patent/IL322482A/en unknown
- 2019-08-20 IL IL280995A patent/IL280995B2/en unknown
- 2019-08-20 DK DK19756180.6T patent/DK3841120T3/da active
- 2019-08-20 LT LTEPPCT/EP2019/072302T patent/LT3841120T/lt unknown
- 2019-08-20 CA CA3110013A patent/CA3110013A1/en active Pending
- 2019-08-20 SI SI201930975T patent/SI3841120T1/sl unknown
- 2019-08-20 SG SG11202101652PA patent/SG11202101652PA/en unknown
- 2019-08-20 JP JP2021534820A patent/JP7434328B2/ja active Active
- 2019-08-20 EP EP19756180.6A patent/EP3841120B1/en active Active
-
2021
- 2021-02-16 ZA ZA2021/01051A patent/ZA202101051B/en unknown
- 2021-02-17 MX MX2025007882A patent/MX2025007882A/es unknown
- 2021-07-06 US US17/368,720 patent/US11345750B2/en active Active
-
2022
- 2022-05-27 US US17/827,488 patent/US12590143B2/en active Active
-
2024
- 2024-02-06 JP JP2024016700A patent/JP7835788B2/ja active Active
-
2026
- 2026-02-20 AU AU2026201303A patent/AU2026201303A1/en active Pending
- 2026-02-20 AU AU2026201302A patent/AU2026201302A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12590143B2 (en) | Antibodies binding to citrullinated histone 2A and/or 4 | |
| JP2021184731A (ja) | Ｃｄ１２７に対する抗体 | |
| WO2021213478A1 (zh) | 抗人b7-h3的单克隆抗体及其应用 | |
| TWI908724B (zh) | TrkA的抗體及其應用 | |
| KR101947758B1 (ko) | 포스포릴콜린에 대한 신규 항체 | |
| EP3016977B1 (en) | Human anti-il-32 antibodies | |
| IL308223A (en) | Prevention of eosinophilic traps | |
| WO2020108636A1 (zh) | 全人抗gitr抗体及其制备方法 | |
| HK40128527A (en) | Antibodies binding to citrullinated histone 2a and/or 4 | |
| EP4085973A1 (en) | Inhibition of eosinophil extracellular traps | |
| EA053252B1 (ru) | Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4 | |
| EA048367B1 (ru) | Антитела, связывающиеся с цитруллинированным гистоном 2а и/или 4 | |
| KR20220143730A (ko) | 단백질을 표적화하는 분자 | |
| CA3071634C (en) | Antibody binding active alpha-synuclein | |
| WO2024153146A1 (zh) | 抗nmda受体自身免疫性脑炎新型抗体及其用途 | |
| CA3071634A1 (en) | Antibody binding active alpha-synuclein |